Dianthus Therapeutics, Inc. (DNTH)

NASDAQ • Healthcare

$106.2

+$2.92 (+2.8%)

Market closed

Last close at September 11, 2026 at 20:00 UTC

Open$106.78

Day Range$105 - $109.79

Avg. Volume (3M)591.1K

Market Cap$5.9B

52 Week Range

$32.22$117.88

Next EarningsIn 53 daysNov 5, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$761K100%

Gross Profitminus cost of goods$761K100%

Fundamentals & Financials

Revenue (TTM)

$1.9M

Net Income (TTM)

-$29.9M

EPS (TTM)

-$0.13

ROA (TTM)

-2.47%

Current Ratio

26.1

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

-2.3%Q3 2025-$0.88

-12.8%Q4 2025-$0.97

-45.9%Q1 2026-$1.43

+27.4%Q2 2026-$0.85

-6.3%Q3 2026-$0.9

Nov 5

in 53 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Miss -6.3%

Dianthus Therapeutics’ EPS trailed consensus in the fiscal second quarter of 2026, reported Aug. 4, even as revenue rose 294.3% to about $761,000. Operating income was a loss of about $61.5 million, and net income was a loss of about $50.2 million, down 58.8% from a loss of about $31.6 million a year ago. EPS of -$0.90 trailed the -$0.85 estimate, -6%, and was down 2.3% from -$0.88 a year ago. Consensus for the next period calls for EPS of -$1.02 on revenue of $400,833.00.

View full earnings history

About Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc. is a NASDAQ-listed biotechnology company developing therapies for patients with severe autoimmune diseases. In qualitative terms, it is a clinical-stage healthcare company built around an early pipeline rather than commercialized products, with its work centered on two named candidates: claseprubart and DNTH212.

Name

Dianthus Therapeutics, Inc.

CEO

Marino Garcia

Website

dianthustx.com

Industry

Healthcare

Year Founded

2019

Employees

Today's Snapshot

AI-generated

DNTH closed 2.8% higher at 106.20, while its sector was flat. JPMorgan, an investment bank, rated Dianthus Overweight and set a $135 price target.

Trading Volume

Above 10d avg 590.6K

732.7K

vs S&P 500 Today

Outperforming Market

+1.90%

Updated: September 11, 2026 at 20:22 UTC

Technical Indicators

3 Buy2 Neutral3 Sell

DNTH shows short-term weakness within a longer-term supportive structure: momentum and MACD are negative and the 10- and 20-day averages sit above the current price, signaling near-term pressure, while the 50/100/200-day averages remain well below, indicating longer-term support. Momentum indicators such as RSI are neutral and ADX is low, implying the trend lacks conviction, and ATR suggests moderate intraday range. OBV is positive, which contrasts with the short-term sell signals and points to some accumulation. Technical takeaway: Sell—near-term bearish momentum amid longer-term support and low trend strength.

All signals

EMA (5 indicators)$78.40 - $107.85
Buy
RSI (14)47.62
Neutral
Stochastic %K (14, 3, 3)30.61
Neutral
MACD Level (12, 26)-0.24
Sell

Peers & Related Assets

ELVNEnliven Therapeutics, Inc.

$54.32-3.4%

TSHATaysha Gene Therapies, Inc.

$5.02-2.7%

ANABAnaptysBio, Inc.

$53.87-2.3%

SANASana Biotechnology, Inc.

$3.13+1.3%

ATAIAtai Beckley Inc.

NKTRNektar Therapeutics

Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.